AEON Biopharma Inc. (AEON) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

AEON Biopharma, Inc.

NYSE MKT | AEON

0.41

USD

+0.0051 (+1.28%)

AT CLOSE (AS OF Apr 17, 2025)

$4.3M

MARKET CAP

0.0001

P/E Ratio

5250.96

EPS

$402

52 Week High

$0.38

52 Week Low

REAL ESTATE & CONSTRUCTION

Sector

AEON Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

AEON Technicals

Tags:

AEON Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	-
Total Revenue	$0
Cost Of Revenue	-
Costof Goods And Services Sold	-
Operating Income	$73M
Selling General And Administrative	$14M
Research And Development	$14M
Operating Expenses	-$73M
Investment Income Net	-
Net Interest Income	-
Interest Income	-
Interest Expense	-
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$97K
Income Before Tax	$42M
Income Tax Expense	-
Interest And Debt Expense	-
Net Income From Continuing Operations	$42M
Comprehensive Income Net Of Tax	-
Ebit	-$28M
Ebitda	-$28M
Net Income	$42M

Revenue & Profitability

Earnings Performance

AEON Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$3.1M
Total Current Assets	$1.6M
Cash And Cash Equivalents At Carrying Value	$13K
Cash And Short Term Investments	$13K
Inventory	-
Current Net Receivables	-
Total Non Current Assets	$1.6M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	-
Long Term Investments	-
Short Term Investments	-
Other Current Assets	$1.6M
Other Non Current Assets	-
Total Liabilities	$32M
Total Current Liabilities	$14M
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	$121K
Total Non Current Liabilities	$18M
Capital Lease Obligations	$1.3M
Long Term Debt	$12M
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$13M
Other Current Liabilities	$7.5M
Other Non Current Liabilities	$3.5M
Total Shareholder Equity	-$29M
Treasury Stock	-
Retained Earnings	-$432M
Common Stock	$4K
Common Stock Shares Outstanding	$8K

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$20M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$97K
Capital Expenditures	$0
Change In Receivables	-
Change In Inventory	-
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$15M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	$42M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	-
Total Revenue	$0
Cost Of Revenue	-
Costof Goods And Services Sold	-
Operating Income	$73M
Selling General And Administrative	$14M
Research And Development	$14M
Operating Expenses	-$73M
Investment Income Net	-
Net Interest Income	-
Interest Income	-
Interest Expense	-
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$97K
Income Before Tax	$42M
Income Tax Expense	-
Interest And Debt Expense	-
Net Income From Continuing Operations	$42M
Comprehensive Income Net Of Tax	-
Ebit	-$28M
Ebitda	-$28M
Net Income	$42M

AEON Profile

AEON Biopharma, Inc. Profile

Sector: REAL ESTATE & CONSTRUCTION

Industry: BLANK CHECKS

AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. The company is headquartered in Newport Beach, California.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.00	9.68%	-	409,386,220
STSS	$0.03	20.75%	$522.68K	391,799,240
NVDA	$101.49	-2.87%	$2.48T	292,517,465
HTZ	$8.24	44.31%	$2.54B	266,908,117
FMTO	$0.02	-35.81%	$2.41M	198,396,141

Symbol	Price	Change %	Market Cap	Volume
PLD	$102.10	1.80%	$94.64B	6,213,179
O	$58.32	1.85%	$52.01B	5,109,606
DHI	$121.25	3.16%	$38.90B	6,395,744
VICI	$32.54	1.53%	$34.39B	8,361,661
VRT	$73.21	2.18%	$27.88B	9,296,487

Symbol	Price	Change %	Market Cap	Volume
MSGM	$2.75	145.54%	$8.75M	36,058,545
SXTC	$2.16	118.42%	$29.73M	51,508,885
ADGM	$1.78	92.81%	$54.65M	114,733,769
PNBK	$3.28	73.55%	$13.04M	1,511,087
RTC	$0.37	72.09%	$10.86M	187,018,434

Symbol	Price	Change %	Market Cap	Volume
JEWL	$0.00	-90.83%	$2.78M	470,134
LXEH	$6.84	-70.25%	$26.82M	1,373,607
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
MMV	$0.48	-51.02%	$11.90M	1,568,644

Quick Links

AEON $0.41 (+1.28%) Quote details